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years (Bello et al., 1992). BVDV vaccines fail to
control persistent infections, which occur in
animals that are infected in utero at 40-120 days
of gestation, and result in lifelong viral shedding.
Modified-live BVDV vaccines are available, but
they are not safe to use in pregnant animals.
Inactivated BVDV vaccines can be used in a
pregnant animal, but they are inconvenient and
ineffective at controlling persistent infections
(Baker, 1995).

Abstract
A recently developed recombinant bovine
herpesvirus 1 (BHV-1) virus containing the
envelope protein gp53 of bovine viral diarrhea
virus (BVDV) type 1, BHV-1 (v1V31), was
assessed for its ability to protect against BVDV
in calves.
Four calves were vaccinated
intranasally with the recombinant BHV-1-BVDV
vaccine and did not exhibit any clinical signs
following vaccination. The vaccine virus was
recovered from all vaccinated calves on days 8
through 10 and the replication appeared to be
restricted to nasal passages. Twenty-eight days
after vaccination, the four vaccinated and four
control calves were challenged with the type 1
BVDV, strain NY-1.
All calves had slight
temperature elevations but the clinical signs
were more severe in the control calves. The
platelet counts were significantly depressed in
the control calves. Prior to challenge, neither
group had BVDV serum neutralizing antibody.
The vaccinated calves developed higher serum
antibody levels 2 months following challenge,
indicating a secondary immune response.
Necropsy was performed six weeks following
infection. No latent BHV-1 virus was detected
from the trigeminal ganglion of any of the
vaccinated calves. The recombinant BHV-1
virus vaccine containing a single BVDV protein
provided partial protection against BVDV
infection.

BHV-1 is useful as an expression and vaccine
vector (Bello et al. 1992). Genes from other
viruses can be inserted into the BHV-1
thymidine kinase (TK) gene because the TK
gene is non-essential for BHV-1 replication in
cattle and TK-BHV-1 viruses protect pregnant
cows against abortion (Whetstone et al. 1992).
This led to the development of the BHV-1-BVDV
recombinant virus, BHV-1 (v1V31).
The
glycoprotein 53 (gp53) of BVDV is the major
target for neutralizing antibody against BVD
virus. The gp53 from BVDV was inserted into
the TK locus of a TK-- BHV-1 genome. This
work was done by Dr. L.J. Bello and Dr. W.C.
Lawrence, University of Pennsylvania (data not
published).
The use of a BHV-1-BVDV recombinant virus
vaccine in pregnant cattle to control both BHV-1
and BVDV abortions and BVDV persistent
infections of the fetuses is an important and
promising approach. This preliminary vaccine
trial using calves is a model for future trials to
protect pregnant cows against BHV-1 and BVDV
infection. The objective of this study was to
determine if the BHV-1 recombinant virus
vaccine was safe and efficacious.

Introduction
Bovine viral diarrhea virus (BVDV) and bovine
herpesvirus 1 (BHV-1) infections are a major
source of respiratory and reproductive problems
in cattle (Fields et al., 1996; Ludwig, 1983). Live
attenuated BHV-1 vaccine strains are effective
and have been used safely in cattle for several
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Viruses and Cells. The vaccine virus used was
the recombinant BHV-1 (v1V31) containing gp53
of the NADL strain of BVDV type 1 was
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prepared at the University of Pennsylvania in
Philadelphia, PA. The cells used for all assays
were bovine turbinate (Bt) cells. The cells were
grown in minimum essential media (MEM)
containing 5% fetal bovine serum (FBS). The
challenge virus used was type 1 BVDV NY-1
from
the
National
Veterinary
Services
Laboratory in Ames, IA. BVDV Singer type 1
and BVDV A125 type 2 strains were used for the
BVDV type 1 and type 2 serum neutralization
assays respectively.

The vaccinated and control group calves were
intranasally inoculated with 107.9TCID50/2ml of
NY-1 BVDV on day 28 of the study. Nasal
samples were taken days 28 through 35 to
monitor for BVDV excretion. Clinical signs were
taken every day with the same categories and
ratings as the pre-challenge period. Serum
samples were taken every 7-14 days from 0- 90
days to monitor for BHV-1 or BVDV
seroconversion. Whole blood was taken days
28 through 38 to count the number of whole
blood cells and platelets.

Animals. Eight male, BHV-1 and BVDV
negative, Holstein calves were used in the
study. The calves were four to five months old
and ranged in weight from 200 to 300 pounds.
Two groups of calves were used, a vaccinated
group and a control group, with each group
consisting of four animals. The calves were
initially housed first in an open enclosure with
calf hutches and later moved to an open-front
barn in a small pasture enclosure. The study
was reviewed and approved by the SDSU
Institutional Animal Care and Use Committee
(IACUC).

Virus Isolation and Serology. The nasal samples
taken after vaccination and challenge were
collected and virus isolations were performed.
The secretions were collected by aspiration
using a vacuum pump. One-half of a milliliter
(0.5 ml) of nasal secretions were added to 4.5
ml of MEM containing 1% FBS. This mixture
was vortexed, centrifuged and filter sterilized in
0.45 mm filters. Duplicates were plated at 1:5
serial dilutions on Bt cells. The BHV-1 isolation
plates after vaccination were read four days
after inoculation and the cytopathic effect (CPE)
was recorded. Seven days after the inoculation,
the cells on the BVDV isolation plates were fixed
with 20% acetone, 80% PBS and 0.02% BSA.
The plates were dried overnight and frozen at 70°C. Later a BVDV immunoperoxidase test
was performed on the cells to detect BVDV in
the samples (Saliki, 1997). The viral titers were
determined using a TCID50 assay (Karber,
1931).

Vaccination and Challenge Studies. Calves
were vaccinated and/or challenged intranasally.
The calves were secured in a headgate and
restrained using a rope halter. A small plastic
biosafety bag was placed over their muzzles to
induce hypoxia for 1-2 minutes to increase
respiration rate and inspiration volume. The bag
was removed and the vaccine/challenge was
administered with a Chromist TLC aerosol unit
(Gelman Sciences) for one minute to each
nostril. The bag was again placed over the
calves’ muzzles and hypoxia was induced. The
halter was removed and the calves were
released.

Antibody levels for BHV-1 and BVDV were
determined by a virus neutralization assay using
two fold dilutions (Manual of Standards for
Diagnostic Tests and Vaccines, 1992) by the
Serology Section of the Animal Disease
Research and Diagnostic Laboratory (ADRDL)
at SDSU.

The vaccinated calves were intranasally
inoculated with 107TCID50/2ml of recombinant
BHV-1-BVDV vaccine on day 0. Nasal samples
were taken day 0 to 14 to monitor for
recombinant BHV-1-BVDV excretion. Clinical
signs were taken every day. The clinical signs
included respiration, attitude, nasal discharge,
temperature, and diarrhea. The clinical signs
were rated on a 0 to 4 point scale, (i.e. normal
nasal discharge=0, whereas thick or crusted
nasal discharge=4). Serum samples were taken
every seven days starting at day 0 to monitor for
seroconversion to recombinant BHV-1-BVDV.

Clinical Pathology. White blood cell and platelet
counts were performed by the Clinical Pathology
section at the ADRDL of SDSU from the whole
blood on days 27-38 (Days –1 to 10 post
challenge).
Necropsy. The calves were all euthanized by
electrocution at the end of the study on Day 90.
The tissues harvested were: tonsil, spleen,
thymus, testes, Peyer’s patches, trigeminal
ganglion,
and
medistineal,
mesenteric,
retropharyngeal, and subiliac lymph nodes.
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Paired tissue samples were taken, one set was
fresh and one set was preserved in formalin.
The fresh tissues were frozen in -80°C. Virus
isolations were performed on these samples.

Serology. The initial development and kinetics
of BVDV type 1 serum neutralization response
was similar between the vaccinates and control
animals with the exception of the BVDV type 1
titers of the vaccinated group which were higher
at day 90 (Figure 8). All of the calves seroconverted to BVDV type 1 by day 56 of the study
(28 days post-challenge) (Figure 8). Interestingly
none of the vaccinated calves seroconverted to
BHV-1 (data not shown). The response to
serotype 2 was low indicating low cross
reactivity between BVDV type 1 NY-1 strain and
BVDV type 2 A125 (Figure 8). The values for
Calf #4 were excluded from the data because of
a high outlying BVDV type 2 titer on a single
day.

Statistical Analysis. The results were analyzed
using a student's T-test for statistical
significance.
Results
Growth of Recombinant Virus and Clinical Signs
following Vaccination. BHV-1 was recovered
from all animals from days 3-10 days postvaccination (Figure 1). The most consistent
days were days 8-10. Titers of the recombinant
recovered from the nasal secretions were as
high as 106 TCID50/ml.

Discussion
This study established that a recombinant BHV1-BVDV was safe to use in calves. The calves
showed minimal reactions to the vaccine as
measured by body temperatures and clinical
scores. These minimal symptoms coincided
with the detection of the recombinant BHV-1BVDV shedding in the nasal secretions of the
vaccinated calves (Figure 1). This indicated that
local replication occurred.
Interestingly, no
apparent systemic replication occurred as no
latency could be detected in the trigeminal
ganglia during the necropsy.

The post-vaccination temperatures were normal
(Figure 2) and clinical scores for postvaccination were negligible (Figure 3) with a
very slight increase seen from days 5-8.
Clinical Signs and Virus Isolation Following
Challenge. BVDV was not detected from any
nasal samples after challenge (data not shown).
No latent BHV-1 was detected from the
trigeminal ganglion of any of the vaccinated
calves (data not shown)
The post-challenge temperatures of the
vaccinated and control calf groups were similar
(Figure 4). The post-challenge clinical scores
showed an increase in signs during day 5 to 6
and day 8 to 9 with the control group scores
always higher (Figure 5). However none of the
differences were significant.

After challenge, the vaccinated animals
exhibited less clinical disease than the controls
although none of the differences were significant
(p>0.10). The clinical pathology results indicated
a significant increase in white blood cells in the
control animals on day 35 while there was no
effect on the vaccinated animals. Transient
leukopenia normally associated with BVDV
infection did not occur in this study. There was
a significant thrombocytopenia present in the
control animals on days 34, 36 and 37.

Clinical Pathology. The white blood cell (WBC)
count of both the vaccinated and control calf
group declined on days 1-2 post challenge
(Days 29 and 30) (Figure 6). The vaccinated
calves remained slightly lower than normal on
days 4-6 post challenge and returned to normal
on day 7. The control calves WBC count was
returned to normal on day 5 post-challenge and
increased significantly on day 7 (p <0.10)
(Figure 6). The platelet count of the vaccinated
calf group remained normal after challenge,
while the control calf group’s count was
depressed significantly on days 34 (p<0.1), 36
(p<0.001) and 37 (p<0.05) (Figure 7).

Serum
neutralizations
indicated
the
development of neutralizing antibody titers to
BVDV type 1, but not to the BVDV type 2 (Figure
8). This shows the specificity of type 1 gp53 for
type 1 and not for BVDV type 2. After the
challenge there was an increase in the
vaccinated BVDV type 1 titer at 90 days post
vaccination compared to the control BVDV type
1 titers. This represents a secondary immune
response in the vaccinated animals, showing the
vaccine had induced memory cell development
to BVDV.
3

would provide significant information towards
creating a successful vaccine to control both
BHV-1 and BVDV abortions and BVDV
persistent infections of the fetus.

In conclusion, this small pilot study suggests a
role for a recombinant BVDV-BHV-1 vaccine in
the control of respiratory and reproductive
disease caused by these two viruses. Calves
vaccinated with recombinant BHV-1-BVDV virus
vaccine showed no adverse reactions to the
vaccine and the vaccine replicated locally in the
respiratory tract. There were differences in the
post-challenge clinical scores and type 1 BVDV
serum neutralization titers and significant
differences in the WBC and platelet counts
between the vaccinated and control calves. The
recombinant BHV-1-BVDV vaccine provided
partial protection against a BVDV challenge.
This study suggests a trial with pregnant cows
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Fig.1 Recombinant BHV-1 shedding in nasal secretions after intra-nasal
inoculation.
100000

10000

1000

100

10

1
1

2

3

4

5

6

7

8

9

10

Day post-vaccination

11

13
Animal#2
Animal#4

14
Animal#3
Animal#5

Fig. 2 Post-vaccination average calf rectal-temperature values.
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Fig. 3 Average post-vaccination calf clinical scores.
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Fig. 4 Body Temperatures following BVDV Challenge
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Fig. 5 Clinical Scores following BVDV Infection
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Fig. 6 White Blood Cell Counts following BVDV Infection
16

14

12

10

8

6

AVERAGE VACCINATED
AVERAGE CONTROL

4
27

28

-1

29
1

Challenge

30
2

31
3

32
4

33

5

6

Day

7

34
7

35
8

9

36

37

Fig. 7 Average calf-blood platelets counts following challenge with NY-1 BVDV.
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Fig.8: Singer "BVDV-1" and A125 "BVDV-2" average neutralizing antibody titers in
sera of vaccinated and control calves.
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